T A B L E O F C O N T E N

Background
Transurethral radiofrequency collagen denaturation is a relatively novel, minimally invasive device-based intervention used to treat individuals with urinary incontinence (UI). No systematic review of the evidence supporting its use has been published to date.
Objectives
To evaluate the efficacy of transurethral radiofrequency collagen denaturation, compared with other interventions, in the treatment of women with UI.
Review authors sought to compare the following.
• Transurethral radiofrequency collagen denaturation versus no treatment/sham treatment.
• Transurethral radiofrequency collagen denaturation versus conservative physical treatment.
• Transurethral radiofrequency collagen denaturation versus mechanical devices (pessaries for UI).
• Transurethral radiofrequency collagen denaturation versus drug treatment.
• Transurethral radiofrequency collagen denaturation versus injectable treatment for UI.
• Transurethral radiofrequency collagen denaturation versus other surgery for UI.
Search methods
We conducted a systematic search of the Cochrane Incontinence Group Specialised Register (searched 19 December 2014), EMBASE and EMBASE Classic (January 1947 to 2014 Week 50), Google Scholar and three trials registries in December 2014, along with reference checking. We sought to identify unpublished studies by handsearching abstracts of major gynaecology and urology meetings, and by contacting experts in the field and the device manufacturer.
Selection criteria
Randomised and quasi-randomised trials of transurethral radiofrequency collagen denaturation versus no treatment/sham treatment, conservative physical treatment, mechanical devices, drug treatment, injectable treatment for UI or other surgery for UI in women were eligible.
Data collection and analysis
We screened search results and selected eligible studies for inclusion. We assessed risk of bias and analysed dichotomous variables as risk ratios (RRs) with 95% confidence intervals (CIs) and continuous variables as mean differences (MDs) with 95% CIs. We rated the quality of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach.
Main results
We included in the analysis one small sham-controlled randomised trial of 173 women performed in the United States. Participants enrolled in this study had been diagnosed with stress UI and were randomly assigned to transurethral radiofrequency collagen denaturation (treatment) or a sham surgery using a non-functioning catheter (no treatment). Mean age of participants in the 12-month multicentre trial was 50 years (range 22 to 76 years).
Of three patient-important primary outcomes selected for this systematic review, the number of women reporting UI symptoms after intervention was not reported. No serious adverse events were reported for the transurethral radiofrequency collagen denaturation arm or the sham treatment arm during the 12-month trial. Owing to high risk of bias and imprecision, we downgraded the quality of evidence for this outcome to low. The effect of transurethral radiofrequency collagen denaturation on the number of women with an incontinence quality of life (I-QOL) score improvement ≥ 10 points at 12 months was as follows: RR 1.11, 95% CI 0.77 to 1.62; participants = 142, but the confidence interval was wide. For this outcome, the quality of evidence was also low as the result of high risk of bias and imprecision.
We found no evidence on the number of women undergoing repeat continence surgery. The risk of other adverse events (pain/dysuria (RR 5.73, 95% CI 0.75 to 43.70; participants = 173); new detrusor overactivity (RR 1.36, 95% CI 0.63 to 2.93; participants = 173); and urinary tract infection (RR 0.95, 95% CI 0.24 to 3.86; participants = 173) could not be established reliably as the trial was small. Evidence was insufficient for assessment of whether use of transurethral radiofrequency collagen denaturation was associated with an increased rate of urinary retention, haematuria and hesitancy compared with sham treatment in 173 participants. The GRADE quality of evidence for all other adverse events with available evidence was low as the result of high risk of bias and imprecision.
We found no evidence to inform comparisons of transurethral radiofrequency collagen denaturation with conservative physical treatment, mechanical devices, drug treatment, injectable treatment for UI or other surgery for UI.
Authors' conclusions
It is not known whether transurethral radiofrequency collagen denaturation, as compared with sham treatment, improves patientreported symptoms of UI. Evidence is insufficient to show whether the procedure improves disease-specific quality of life. Evidence is also insufficient to show whether the procedure causes serious adverse events or other adverse events in comparison with sham treatment, and no evidence was found for comparison with any other method of treatment for UI.
P L A I N L A N G U A G E S U M M A R Y
Low-temperature heat via the urethra to treat women with urinary leakage
Review question
We studied the question of whether using low-temperature heat via the urethra is safe and helps women with involuntary urinary leakage. We looked for randomised studies comparing this treatment with no treatment or with other treatment forms.
Background
Involuntary urinary leakage is a troubling problem that many women face. Many types of treatment are available to help these women, such as changes in behaviour and different types of surgery. Low-temperature heat via the urethra is a newer form of treatment that can be used to treat women in the office rather than in the operating room. How well this treatment works and how safe it is are not well understood.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Transurethral radiofrequency collagen denaturation compared with no treatment/sham treatment for women with UI a Downgraded for study limitations (-1): high risk of bias. b Downgraded for imprecision (-1): no events in small study. c Downgraded for imprecision (-1): confidence interval includes both no effect and appreciable benefit; low numbers of events. d Downgraded for imprecision (-1): confidence interval includes no effect and both appreciable benefit and appreciable harm; low numbers of events.
B A C K G R O U N D Description of the condition
Stress urinary incontinence (SUI) is defined as the involuntary leakage of urine associated with effort, coughing or exertion (Abrams 2002). Mixed urinary incontinence (MUI) is the involuntary leakage of urine associated with urgency and also with exertion, sneezing or coughing.
Pathophysiology
Stress urinary incontinence is thought to have a complex and multi-factorial pathophysiology that relates to general weakening of the pelvic musculature and of collagen-dependent tissues involved in pelvic support (Long 2008). Two mechanisms are well described in the literature.
• Loss of urethral support (bladder neck hypermobility).
• Rotational descent of the proximal urethra with loss of internal urethral integrity (urinary sphincter deficiency) as evidenced by funnelling within the proximal urethra (Schorge 2008).
Epidemiology
An estimated 38% of women in the United States experience some type of urinary incontinence (UI); SUI is the most common ( Abrams 2002; Anger 2006). It is estimated that more than 30% of women 40 years of age or older have SUI. It has been shown that the annual incidence of SUI increases with age and has been reported as approximately 9% in women over 65 years of age (Imamura 2010).
Risk factors
Major risk factors for female SUI include pregnancy, vaginal delivery, parity, age, postmenopausal status and obesity (MacArthur 2006; MacLennan 2000; Thom 1997) . Childbearing is the main predisposing factor specific for the development of SUI; however, the exact mechanism is unclear. Gynaecological surgery for prolapse, hysterectomy and other gynaecological procedures double the risk of SUI (Allahdin 2008; Hampel 2004).
Diagnosis
Initial assessment of UI may include a review of the medical history, physical examination findings, a urinary diary and an incontinence questionnaire such as the International Consultation on Incontinence (ICI) Questionnaire-Short Form (ICIQ-SF for Urinary Incontinence) (Avery 2004). Urodynamics is an invasive clinical test requiring catheterisation that allows further categorisation of incontinence according to the underlying functional or anatomical cause. Its use is generally limited to individuals for whom more accurate categorisation is important (e.g. before surgical treatment) (Imamura 2010).
Treatment
Treatment for UI can be divided into non-surgical and surgical modalities. Treatment choice greatly depends on patient preference and on additional factors such as symptom severity, degree of interference with lifestyle, presence of related problems and degree of co-morbidities.
Conservative and pharmacological treatment
Non-surgical treatment options for UI usually have few adverse effects and thus are often utilised first in the treatment of UI. Several Cochrane reviews have detailed these options, which may include:
• lifestyle changes (weight loss, bladder training) (Wallace 2004);
• pelvic floor muscle training (PFMT) (Ayeleke 2013; Dumoulin 2014);
• use of devices such as pessaries or vaginal cones (Herbison 2013); and
• off-label usage of pharmacological agents (oestrogen, serotonin or noradrenaline reuptake inhibitors) (Cody 2012; Mariappan 2005).
Surgical treatment
Previous Cochrane reviews have assessed the effects of different surgical procedures performed to treat women with UI. Although the Burch colposuspension was previously considered the "gold stan- Transurethral radiofrequency collagen denaturation consists of a radiofrequency probe with a palpable balloon that is placed into the proximal urethra, where radiofrequency needles are deployed into the submucosa. Sixtysecond cycles are delivered in nine positions to a total of 36 sites using a 21F transurethral delivery probe connected to a radiofrequency generator. Perceived advantages of this procedure are that it can be done in the office setting with the patient under local anaesthesia or intravenous sedation, without imaging, in less than one hour. Transurethral radiofrequency collagen denaturation is reported to be simpler than radiofrequency treatment of the endopelvic fascia and is performed using a standardised technique that is easily reproducible. It offers the additional advantage of not requiring laparoscopic or vaginal incisions, thus reducing the morbidity of the procedure.
Description of the intervention
How the intervention might work
Transurethral radiofrequency collagen denaturation administers low-temperature radiofrequency energy through a transurethral probe aimed to induce submucosal collagen denaturation while decreasing regional tissue compliance. The decrease in regional dynamic tissue compliance without tissue necrosis is intended to result in functional rather than anatomical change (Takacs 2010). Specifically, when collagen of the urethra is heated in the range of low-temperature radiofrequency energy that is administered by transurethral radiofrequency collagen denaturation (range of 65°C), large domains of consecutive, intramolecular hydrogen bonds are broken, decreasing overall extensibility, and thus reducing urethral compliance (Chen 1998; Wright 2002). The maximal diameter of the urethra is reduced, stretching the surrounding urethral muscles and allowing them to function more effectively (Larson 2002) . It is proposed that these mechanisms cause a decrease in funnelling and an increase in the functional length of the urethra.
Why it is important to do this review
Transurethral radiofrequency collagen denaturation was approved through the FDA 510(k) pre-market notification approval process, by which new surgical devices can be approved without additional human testing if they are substantially similar to devices already on the market, and thus are not subject to pre-market approval. Transurethral radiofrequency collagen denaturation of the urethra was approved on the basis of the previous success of RFA of metastatic liver lesions and benign prostatic hyperplasiavery dissimilar disease processes. As a result of these low evidentiary standards, considerable uncertainty remains about the true therapeutic effectiveness and risks associated with this surgical device. In the United States, transurethral radiofrequency collagen denaturation is being marketed directly to consumers, and industry-funded studies advocate the procedure as effective, safe and cost-effective (Sand 2014a). Although considered investigational by many insurance providers, the procedure has a specific common procedural terminology (CPT) code (53860) to allow billing and provider reimbursement. The company website states that "the Lyrette Procedure is covered by Medicare in most states and by numerous other health insurance companies" and lists physicians throughout the United States who offer the procedure (lyretterf.com/find-a-physician). We were unable to find information about the availability of this procedure in other countries. To date, no study has critically assessed the quality of evidence supporting the use of transurethral radiofrequency collagen denaturation, nor has any study systematically evaluated its benefits and harms. Given the availability of multiple treatment alternatives, the uncertain risks and the associated costs, an investigation of the efficacy of transurethral radiofrequency collagen denaturation appears important.
O B J E C T I V E S
To evaluate the efficacy of transurethral radiofrequency collagen denaturation, compared with other interventions, in the treatment of women with urinary incontinence (UI).
M E T H O D S Criteria for considering studies for this review
Types of studies
We included parallel-group randomised or quasi-randomised trials; we excluded cluster-randomised and cross-over trials.
Types of participants
Adult female patients with SUI or MUI diagnosed clinically or with urodynamics.
Types of interventions
Investigators compared transurethral radiofrequency collagen denaturation with sham treatment, no treatment, conservative physical treatment, mechanical devices (pessaries for UI), drug treatment, injectable treatment for UI or other surgery for UI.
Types of outcome measures
Measurement of outcomes assessed in this review was not a criterion for inclusion.
Primary outcomes
Participant-reported measures
Number of women reporting UI symptoms after intervention at time points defined by investigators.
Serious adverse events
Major vascular or visceral injury, bladder/urethral perforation, nerve damage, fistula formation or other major surgical complications.
Disease-specific quality of life
Disease-specific quality of life assessed through validated measures.
Secondary outcomes
Repeat continence surgery
Number of women undergoing repeat continence surgery.
Participant observations
• Overactive bladder symptoms, urgency UI.
Quantification of symptoms
• Number of pad changes.
• Pad tests (weights).
• Other quantification of symptom measures reported by individual trials.
Clinician observations
Objective measurement of incontinence (i.e. direct observation upon examination, leakage observed at urodynamics or other objective clinician observations of incontinence).
Other quality of life
• General health status measures (e.g. Short Form 36) (Ware 1993).
• Other quality of life measures reported by individual trials.
Surgical outcome measures
• Length of hospital stay.
• Time to return to normal activity level.
• Operative blood loss.
• Other surgical outcome measures reported by individual trials.
Other adverse events
• Pain, dysuria.
• (New) detrusor overactivity.
• De novo urinary retention.
• Urinary tract infection.
• Haematuria.
• Dyspareunia.
• New prolapse.
• Other adverse events reported by individual trials.
Main outcomes for 'Summary of findings' table
• Number of women reporting UI symptoms.
• Serious adverse events.
• Disease-specific quality of life.
• Repeat continence surgery.
• Pain/dysuria.
Search methods for identification of studies
We performed a comprehensive search on 11 January 2014 that was rerun on 19 December 2014 for both published and unpublished studies without language or other restrictions. We employed both electronic and manual searches.
Electronic searches
We searched the Cochrane Incontinence Group Specialised Register (for details, see Appendix 1), EMBASE and EMBASE Classic via Ovid SP (for search strategy, see Appendix 2) and Google Scholar (see Appendix 3) to identify relevant trials. We contacted manufacturers for information on relevant trials. We searched the FDA website (www.fda.gov/MedicalDevices/default.htm; see Appendix 4) for additional relevant documents or studies leading to approval of transurethral radiofrequency collagen denaturation. We applied no language or other restrictions. For studies identified, we contacted study authors and/or sponsors to clarify information or to request additional data points, as necessary. In addition, we searched the following clinical trials registries.
• Current Controlled Trials: www.controlled-trials.com (see Appendix 5).
• ClinicalTrials.gov: www.clinicaltrials.gov (see Appendix 6).
• World Health Organization International Clinical Trials Registry Platform (WHO ICTRP): www.who.int/ictrp/en (see Appendix 7).
Searching other resources
We scrutinised the reference lists of identified relevant studies for additional citations. We contacted specialists in the field to ask for possible unpublished data. In addition, we 
Data collection and analysis
Selection of studies
Two review authors (DK and JH) independently screened the trials for eligibility. They consulted a third review author (MLM or PD) when there was disagreement, which was also recorded. They obtained full-text articles of eligible studies and listed studies that were formally considered for the review but were excluded along with reasons for their exclusion.
Data extraction and management
Studies that met the inclusion criteria passed to the stage of data abstraction. Two review authors (DK and JH) independently conducted data abstraction using a standardised data abstraction form, which had been pilot-tested. Extracted data included study design; dates when the study was conducted; setting; participant inclusion and exclusion criteria; participant age; sample size of the study and of each intervention group; details of interventions; details of outcomes relevant to the review including how measured, time points at which they were measured and outcomes data; details of funding sources; declarations of interest among primary study authors; and study details relevant to risk of bias assessment. Analysis was based on available data from included trials relevant to comparisons and outcomes of interest. Review authors presented and considered data according to the comparisons and grouped them by outcomes. They resolved differences of opinion related to data abstraction by consensus and/or through discussion with a third review author (MLM or PD).
Assessment of risk of bias in included studies
Two review authors (DK and JH) evaluated all relevant clinical studies independently to assess methodological quality. They resolved disagreements by discussion with a third review author (MLM or PD). Each review author undertook assessment of methodological quality using the tool for assessing risk of bias of The Cochrane Collaboration (Higgins 2011a). We assessed the following domains as having low, unclear or high risk of bias.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective reporting.
• Other sources of bias.
We assessed blinding of participants and personnel, blinding of outcome assessment and incomplete outcome data on an outcomespecific basis, as the risk of bias of each of these domains is likely to vary by outcome. We grouped outcomes as subjective and objective for outcomespecific risk of bias assessments in blinding domains. For the three primary outcomes, we considered the number of women reporting UI symptoms and disease-specific quality of life as subjective outcomes, whereas we categorised occurrence of a serious adverse event as an objective outcome.
We rated as subjective all secondary outcomes except for quantification of symptoms (e.g. number of pad changes), length of hospital stay, operative blood loss, occurrence of haematuria, urinary tract infection, urinary retention, repeat continence surgery, new prolapse and objective measurement of incontinence (e.g. change in leak point pressure). For the incomplete outcome data domain, we grouped outcomes that had similar circumstances related to completeness of data.
Measures of treatment effect
We analysed the extracted data using Review Manager software (RevMan 2014). For dichotomous variables, we extracted numbers of events and totals to calculate risk ratios (RRs) and 95% confidence intervals (CIs). If numbers of events were unavailable, we used reported percentages of participants experiencing the outcome and total numbers of participants assessed to calculate the numbers of events. For continuous outcomes, we extracted means, standard deviations and totals to calculate mean differences (MDs) and 95% CIs.
Unit of analysis issues
We included only randomised and quasi-randomised controlled trials; we excluded cluster-randomised and cross-over trials. Although they were eligible for inclusion, we identified no studies with multiple intervention groups.
Dealing with missing data
We contacted the original investigators to request missing data so we could analyse all data by performing an intention-to-treat (ITT) analysis. However, we obtained no additional data. We therefore based analyses on available data only. We identified non-ITT analyses in the Results section as available case analyses accordingly.
Assessment of heterogeneity
We planned to assess heterogeneity by visually inspecting the forest plots and by using the I 2 statistic (Higgins 2002; Higgins 2003). We defined the thresholds for interpretation of the I 2 statistic according to the Cochrane Handbook for Systematic Reviews of Interventions (Deeks 2011): < 30% heterogeneity may not be important, 30% to 50% may represent moderate heterogeneity and > 50% may represent substantial/considerable heterogeneity. Heterogeneity was not a factor because of the number of studies included in the review.
Assessment of reporting biases
To minimise the impact of possible publication bias, we conducted electronic and manual searches of multiple databases, including registries, without language restriction, to identify published and unpublished studies. Fewer than 10 studies were available; therefore we did not conduct a test for funnel plot asymmetry to assess potential publication bias. We attempted to obtain study protocols to assess for reporting bias.
Data synthesis
We planned to pool data from eligible studies to estimate a pooled effect size and to generate the corresponding forest plots. We planned to perform meta-analysis using a random-effects model with the Mantel-Haenszel method for dichotomous data and with the inverse variance method for continuous data. Given that only a single eligible trial was identified, we conducted no meta-analysis.
Subgroup analysis and investigation of heterogeneity
If relevant data were available (subgroups already stratified in the study), we planned to explore the following potential sources of heterogeneity using subgroup analyses based on four a priori defined hypotheses (with prespecified direction) and to perform additional testing for interaction.
• Participant age (50 years of age vs older; better outcomes in younger participants).
• Menopausal status (before vs after; better outcomes in premenopausal women).
• Presence or absence of prolapse (yes vs no; better outcomes when prolapse was absent).
• History of prior surgical procedure for treatment of individuals with UI (yes vs no; better outcomes with no prior surgical procedure).
Given that limited data were identified, none of the prespecified subgroup analyses were possible. We report a post hoc subgroup analysis performed by degree of baseline UI (mild vs moderate to severe), as provided by the trial investigators.
Sensitivity analysis
We planned to investigate the robustness of results by performing a sensitivity analysis based on methodological quality as defined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b) and to report the results in a summary table. Given the paucity of data, we performed no sensitivity analysis.
'Summary of findings' table
We rated the overall quality of evidence using the GRADE framework, with consideration of study limitations (risk of bias), inconsistency, indirectness, imprecision and publication bias, and we presented this information in a 'Summary of findings' table (Guyatt 2008; Guyatt 2011; Schünemann 2011).
R E S U L T S Description of studies
See Characteristics of included studies and Characteristics of excluded studies.
Results of the search
For this review, we identified 253 records through the search and retrieved 28 full-text articles; of these, we excluded 25 reports of 21 studies and provided reasons in the Characteristics of excluded studies table. None of the abstracts or presentations provided additional relevant trial data that met our study inclusion criteria. One study met eligibility criteria and was included ( 
Included studies
We included in the analysis one sham-controlled randomised trial in women with SUI conducted in the United States of America (Appell 2006). In this study, 110 women underwent transurethral radiofrequency collagen denaturation in the treatment arm and 63 underwent sham treatment in the control arm. Mean participant age was 50 years (range 22 to 76 years), and mean duration of SUI was eight years (range one to 49 years). All participants were treated with the same type of radiofrequency probe (Novasys Medical, Inc., Newark, California) and one of two similar radiofrequency generators (Novasys Medical, Inc.; Curon Medical, Inc., Fremont, California; Appell 2006). Incontinence quality of life (I-QOL) score improvement of 10 or more points and change in leak point pressure (LPP) were assessed at six months and 12 months of follow-up to look for improvement among the two groups. Adverse events and postoperative level of discomfort were also assessed. The study was funded by a grant from Novasys Medical, Inc., the manufacturer of the transurethral radiofrequency collagen denaturation device at that time. For more information, see Characteristics of included studies.
Excluded studies
We excluded 21 studies after performing full-text assessment for eligibility. We excluded four studies because they were observational studies . One study performed a cost analysis of transurethral radiofrequency collagen denaturation (Sand 2014b). Another study was an ongoing multi-centre prospective single-armed trial of transurethral collagen denaturation funded by the Verathon Corporation to study the Lyrette ® device (Lukban 2013a). Results at 12 months of follow-up have been presented at society meetings as abstracts without a full-text study report (Lukban 2013a). As a single-armed study, this trial did not meet inclusion criteria for this review. For more information, see Characteristics of excluded studies. We identified no studies comparing the efficacy of transurethral radiofrequency collagen denaturation versus conservative physical treatment, use of mechanical devices (such as a pessary), drug treatment, injectable treatment or other surgery for UI.
Risk of bias in included studies
We assessed risk of bias on an outcome-specific basis.
Allocation
Random sequence generation
The trial used a computer-generated allocation sequence with a 2: 1 ratio. We judged risk of bias to be low for all outcomes.
Allocation concealment
Allocation concealment was not reported. We rated risk of bias as unclear for all outcomes.
Blinding
We grouped outcomes as subjective and objective for outcomespecific risk of bias assessments in blinding domains.
Blinding of participants and personnel
Although participants were reported to be blinded using a sham design, the study did not report blinding of study personnel. As blinding of personnel was not reported, we judged the risk of performance bias to be unclear for both subjective and objective outcomes.
Blinding of outcome assessment
Blinding of outcome assessors was not reported in the included study. We rated the risk of bias as low for objective outcomes and as unclear for subjective outcomes.
Incomplete outcome data
We grouped categories of outcomes that had similar circumstances related to completeness of data for outcome-specific assessment of the incomplete outcome data risk of bias domain. At 12 months, 82% of the enrolled population were evaluated for ≥ 10-point I-QOL score improvement. Twenty-one women (12%) were lost to follow-up, and eight women had changes in their medical history that excluded them from the study (hysterectomy or urinary tract infection (UTI) at 12 months). As UTI was an adverse event evaluated in the study, the completeness of data for this primary subjective outcome is questionable. Two women had baseline I-QOL scores > 90 and therefore could not have a ≥ 10-point improvement. The percentage of participants in each group who were lost to follow-up or were otherwise considered unevaluable and excluded from analysis was similar. We judged risk of bias for this disease-specific quality of life outcome to be high.
The included study assessed changes in LPP among participants; however only 78.6% were evaluated. A similar percentage of participants in each group was lost to follow-up or was otherwise considered unevaluable and was excluded from analysis. Risk of bias was rated as high for this objective measurement of incontinence. For other outcomes reported in the included study, completeness of outcome data was not reported. We judged risk of bias as unclear for these outcomes.
Selective reporting
In the Methods section, trial investigators reported that the study's main outcomes (≥ 10-point I-QOL score improvement and change in LPP) were assessed at six months and at 12 months; however, no six-month data were presented. We therefore rated the study to be at high risk for selective reporting.
Other potential sources of bias
Investigators provided a subgroup analysis that stratified participants as having mild versus moderate/severe UI at baseline. No trial protocol was available, and investigators provided no rationale for the grouping. We rated this analysis as having high risk of bias and the positive findings as at risk for being spurious. 
Effects of interventions
Participant-reported measures
Number of women reporting UI symptoms after intervention at time points defined by investigators
We found no data reported for this outcome measure (Summary of findings for the main comparison).
Serious adverse events
Major vascular or visceral injury, bladder/urethral perforation, nerve damage, fistula formation or other major surgical complications
No serious adverse events were recorded in the treatment group or the control group during the 12-month trial (one study; 173 participants; Analysis 1.1), although the trial authors did not define 'serious adverse event'. Risk of bias was high and imprecision was a matter of concern for this outcome; the GRADE quality of the evidence was downgraded by two levels to low (Summary of findings for the main comparison).
Disease-specific quality of life
Disease-specific quality of life assessed through validated measures
Transurethral radiofrequency collagen denaturation was not associated with an increase in the number of women with an I-QOL score improvement greater than or equal to 10 points at 12 months when compared with sham treatment in an analysis of available data (RR 1.11, 95% CI 0.77 to 1.62; participants = 142; studies = 1; Analysis 1.2; Figure 2) . We downgraded the quality of the evidence by two levels to low because of high risk of bias and imprecision (Summary of findings for the main comparison). 
Secondary outcomes
Repeat continence surgery
Number of women undergoing repeat continence surgery
We found no available evidence for this outcome (Summary of findings for the main comparison).
Participant observations
Overactive bladder symptoms, urgency UI
We found no available evidence for this outcome.
Quantification of symptoms
Number of pad changes
Pad tests (weights)
Other quantification of symptom measures reported by individual trials
Clinician observations
Objective measurement of incontinence (such as direct observation upon examination, leakage observed at urodynamics or other objective clinician observations of incontinence)
Mean change in LPP at 12 months was -13. Figure 3 ), with a MD less than zero favouring the treatment group. However, the effects were uncertain because evidence was of very low quality as the result of high risk of bias, indirectness and imprecision. 
Other quality of life
General health status measures (e.g. Short Form 36)
Other quality of life measures reported by individual trials
Surgical outcome measures
Length of hospital stay
Time to return to normal activity level
Operative blood loss
Other surgical outcome measures reported by individual trials
The one included study (participants = 173) reported that the level of postoperative discomfort as assessed on a visual analogue scale from 0 (no pain) to 10 (terrible pain) was not significantly different in the treatment arm versus the control arm. However, control group data were not available to the review authors to allow for calculation of the effect estimate and the confidence interval. The quality of the evidence was very low as the result of very serious study limitations and imprecision.
Other adverse events
Pain, dysuria
Dysuria occurred in 9.1% of actively treated participants and in 1.6% of sham-treated participants (RR 5.73, 95% CI 0.75 to 43.70; participants = 173; studies = 1; Analysis 1.4; Figure 4 ). The quality of the evidence was downgraded by two levels to low because of high risk of bias and imprecision (Summary of findings for the main comparison). 
(New) detrusor overactivity
Dry overactive bladder was more common in the transurethral radiofrequency collagen denaturation arm (7.3% vs 3.2%), but this finding was not statistically significant. Very little difference in the prevalence of wet overactive bladder was noted between groups (10% vs 9.5%). When we combined the dry overactive bladder data and the wet overactive bladder data, we found no evidence of a difference in effect on overactive bladder symptoms between groups (RR 1.36, 95% CI 0.63 to 2.93; participants = 173; studies = 1; Analysis 1.5). We downgraded the quality of the evidence to low as the result of high risk of bias and imprecision (Summary of findings for the main comparison).
De novo urinary retention
Urinary retention occurred rarely: One participant in the treatment arm developed urinary retention, and it was unclear as to whether this was of new onset (RR 1.73, 95% CI 0.07 to 41.84; participants = 173; studies = 1; Analysis 1.6; Figure 5 ). We judged the quality of the evidence as low because of high risk of bias and imprecision. 
Urinary tract infection
Urinary tract infection was observed to occur equally when treatment was compared with sham treatment (4.5% vs 4.8%, respectively), and the results were not statistically significant (RR 0.95, 95% CI 0.24 to 3.86; participants = 173; studies = 1; Analysis 1.7). The quality of the evidence was low as the result of downgrades for high risk of bias and imprecision (Summary of findings for the main comparison).
Haematuria
One participant in the treatment arm developed haematuria (0.9%), but this finding was not statistically significant (RR 1.73, 95% CI 0.07 to 41.84; participants = 173; studies = 1; Analysis 1.8; Figure 6 ). Further research is very likely to change the effect estimate because low-quality evidence was downgraded for high risk of bias and imprecision. 
Dyspareunia
New prolapse
Other adverse events reported by individual trials
Hesitancy was reported by one participant in the sham treatment arm (1.6%) and by no participants in the treatment arm (0%), but this finding was not statistically significant (RR 0.19, 95% CI 0.01 to 4.65; participants = 173; studies = 1; Analysis 1.9). High risk of bias and imprecision resulted in downgrading of the quality of the evidence to low.
Subgroup analyses
Given the absence of data, we were unable to perform subgroup analyses based on the pre-identified prognostic variables, which included participant age, menopausal status, presence or absence of prolapse and history of prior surgical procedure for UI.
In an available case subgroup analysis not prespecified in this review, investigators grouped participants on the basis of their level of baseline incontinence into 'mild' and 'moderate to severe' groups. In women with mild incontinence, the RR when treatment was compared with sham treatment for the outcome of number of women with an I-QOL score improvement greater than or equal to 10 points at 12 months was 0.63 (95% CI 0.29 to 1.37; P value 0.24; participants = 69; studies = 1; analysis not shown). In women with moderate to severe incontinence, the RR was 1.49 (95% CI 1.00 to 2.22; P value 0.05; participants = 73; studies = 1; analysis not shown). In these subgroups, according to baseline incontinence, the GRADE quality of the evidence was very low because of downgrading by two levels for high risk of bias and by one level for imprecision. No data were available to permit the same subgroup analyses for other outcomes.
Transurethral radiofrequency collagen denaturation versus conservative physical treatment
We found no available evidence for this comparison.
Transurethral radiofrequency collagen denaturation versus mechanical devices (pessaries for UI)
Transurethral radiofrequency collagen denaturation versus drug treatment
Transurethral radiofrequency collagen denaturation versus injectable treatment for UI
Transurethral radiofrequency collagen denaturation versus other surgery for UI
D I S C U S S I O N Summary of main results
We systematically reviewed the quality of existing evidence on transurethral radiofrequency collagen denaturation for the treatment of female UI. Only one small sham-controlled randomised trial, which enrolled women with SUI, met inclusion criteria for this systematic review (Appell 2006). The trial did not report any evidence with regards to the impact of transurethral radiofrequency collagen denaturation on one of the primary outcomes of the review -the number of women reporting UI symptoms (Summary of findings for the main comparison). The trialists reported that no serious adverse events occurred in either the treatment arm or the control arm of the trial (Summary of findings for the main comparison), but the trial was small and further research is likely to change the estimate. In the included study, investigators found no statistically significant differences in disease-specific quality of life, as measured by the number of women with an I-QOL score improvement greater than or equal to 10 points, between the women who underwent transurethral radiofrequency collagen denaturation and those who underwent sham treatment at 12 months (Summary of findings for the main comparison). However, the trial was small and the confidence intervals wide. The study reported no evidence with regards to the number of women undergoing repeat continence surgery (Summary of findings for the main comparison). The trial was too small to reliably detect differences between groups in the occurrence of other adverse events, such as pain/dysuria, (new) detrusor overactivity, urinary tract infection, urinary retention, haematuria or hesitancy (Summary of findings for the main comparison). We found no trials of comparisons between transurethral radiofrequency collagen denaturation and conservative physical treatment, mechanical devices, drug treatment, injectable treatment for UI or other surgery for UI.
Overall completeness and applicability of evidence
This review highlighted substantial gaps in the evidence, as we were unable to find any studies comparing transurethral radiofrequency collagen denaturation versus five of the predefined types of comparators: conservative physical treatment, mechanical devices, drug treatment, injectable treatment and other surgery for UI. One randomised controlled trial comparing transurethral radiofrequency collagen denaturation versus sham treatment was systematically reviewed. The single included study did not assess our previously stated primary outcome of the number of women reporting UI symptoms after treatment. The one comparison study analysed did not address a number of our secondary outcomes, including the need for further incontinence procedures, dyspareunia and new prolapse development. The trial involved both academic and community urologists and urogynaecologists, thereby enhancing the generalisability of its findings. The most noteworthy exclusion criterion limiting applicability was the exclusion of women with pre-existing overactive bladder symptoms and/or documentation of bladder overactivity. Also, SUI was the only form of UI examined in the trial. Women who had undergone any prior procedure for UI were excluded.
Quality of the evidence
With regards to the primary outcomes of this review, no randomised trial evidence was found to inform our understanding of the impact of transurethral radiofrequency collagen denaturation on individual, patient-reported symptoms of UI. The quality of evidence for the absence of treatment-associated serious adverse events was rated as low, mainly because of concerns over risk of bias and imprecision. The quality of evidence for the outcome of disease-specific quality of life was rated as low because of risk of bias and imprecision. Of particular concern with respect to risk of bias was the failure of study authors to account for all participants in the outcome analysis. We found no evidence for the secondary, main outcome of number of women undergoing repeat continence surgery. The quality of evidence for the other secondary, patient-reported main outcomes was rated as low according to GRADE. We downgraded for risk of bias as well as imprecision. Consideration of inconsistency, indirectness and publication bias did not result in any further downgrading of the quality of evidence for the main outcomes.
Overall, the quality of the body of evidence contributing to the comparison of transurethral radiofrequency collagen denaturation versus sham treatment in this review was low, and evidence was lacking for the other five predefined comparisons.
Potential biases in the review process
Our risk of bias assessment was based on the full-text publication of the study by Appell et al (Appell 2006 ) and the methodolog-ical detail it provided; however, the actual methodological quality of the published study may have been better than reported (Devereaux 2004). Unfortunately, attempts to obtain further information from the principal investigator were limited by his recent passing. The recent change in the company that markets the device in the United States to perform this surgical procedure may have been an additional barrier towards acquiring additional information. We contacted the manufacturer and the secondary authors of the study but received no additional information that would change our assessment of the methodological quality of the study.
Agreements and disagreements with other studies or reviews
A technology assessment and review of the literature on transurethral radiofrequency collagen denaturation was published by the California Technology Assessment Forum in 2008 (Karliner 2008). It does not include several studies that were published after that time period, but it does include an analysis on the modality of laparoscopic and transvaginal radiofrequency denaturation, which has since been withdrawn from the market and was not within the scope of this Cochrane review. A narrative review on transurethral radiofrequency collagen denaturation was published in 2012 (Lukban 2012b). However, it did not apply established systematic review methodology, which includes a comprehensive search for both published and unpublished studies and a critical appraisal of the quality of evidence, as was applied in this Cochrane review.
A U T H O R S ' C O N C L U S I O N S Implications for practice
This systematic review questions the therapeutic efficacy of transurethral radiofrequency collagen denaturation to treat female UI. The included trial was too small to detect any rare serious adverse events, and we were unable to establish the impact of this approach on individual patient-reported UI symptoms. Evidence was insufficient to detect a difference in disease-specific quality of life when compared with sham treatment, and we are uncertain of the findings because the quality of the evidence was low.
Effects of transurethral radiofrequency collagen denaturation compared with conservative physical treatment, mechanical devices, drug treatment, injectable treatment for UI or other surgery for UI are unclear, as we found no available evidence to inform these comparisons.
Implications for research
The findings of this review were based on a single, sham-controlled randomised trial at high risk of bias that did not address patientreported symptoms of UI. Before this intervention is made available to women, more rigorous and adequately powered trials are required to assess the relative benefits and adverse event profile of transurethral radiofrequency collagen denaturation as compared with other minimally invasive, active treatment options such as use of a urethral bulking agent injection or suburethral slings. These trials should be carefully designed and executed with a focus on patient-important outcomes, transparently reported and adequately powered to provide definitive results.
A C K N O W L E D G E M E N T S
The review authors thank the Cochrane Incontinence Group for its support. French transurethral micro-remodeling probe was used and was connected to a radiofrequency generator. All participants were treated with the same type of radiofrequency probe (Novasys Medical, Inc., Newark, California) and 1 of 2 similar types of radiofrequency generator (Novasys Medical, Inc.; Curon Medical, Inc., Fremont, California). After passage into the bladder, a balloon on the probe tip was insufflated to anchor the probe within the bladder outlet. Four 23-gauge needle electrodes were deployed into the urethral submucosa, and radiofrequency was delivered for 60-second intervals. The probe was rotated after each interval until the needles were placed in 9 different positions within the urethra (9 minutes total) Sham treatment (n = 63): Sham treatment also utilised a transurethral probe; however the probe lacked needle electrodes, and the radiofrequency generator was modified so no energy was delivered but the generator appeared and sounded as though energy were being delivered Outcomes Serious adverse events How measured: All adverse events were recorded; no definition of 'serious adverse event' was provided Time points measured: at 1 week, 1 month, 3 months, 6 months and 12 months Time points reported: 12-month prevalence Subgroups: no subgroups reported Disease-specific quality of life How measured: 10-Point or greater improvement in Incontinence Quality of Life (I-QOL) score Time points measured: at 6 months and at 12 months 
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Appell 2006
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
This review is based on a published protocol (Dahm 2012), with differences as described here.
The focus of the review was broadened from 'stress urinary incontinence' to 'urinary incontinence' in accordance with editorial and peer referee feedback.
In the Methods section 'Types of studies', we clarified that we included parallel-group trials and excluded cluster-randomised and crossover trials for consistency with the 'Unit of analysis issues' section of the protocol.
In the Methods section 'Types of outcome measures', we clarified that measurement of outcomes assessed in this review was not a criterion for inclusion. We rephrased the primary outcome 'Participant-reported measures: number of women reporting urinary incontinence symptoms after transurethral collagen denaturation at time points defined by investigators' to be applicable to all interventions assessed in the review; now phrased as 'Participant-reported measures: number of women reporting UI symptoms after intervention at time points defined by investigators'. In accordance with current recommendations that primary outcomes include at least one potential benefit and at least one potential harm (O'Connor 2011), we added two primary outcomes that had been classified among the secondary outcomes in the protocol; these are 'Disease-specific quality of life: disease-specific quality of life assessed through validated measures' and 'Serious adverse events: major vascular or visceral injury, bladder/urethral perforation, nerve damage, fistula formation or other major surgical complications'. To accommodate these changes to the primary outcomes, we made the following changes to the secondary outcomes of the review: removed the patient observations outcome 'Number of women with SUI not improved symptomatically as reported by patient questionnaire, e.g. Incontinence Quality of Life (I-QOL) questionnaire, or other patient observations as reported by individual trials'; changed the 'Quality of life' outcome heading to 'Other quality of life'; removed the quality of life outcome 'Condition-specific health measures (specific instruments designed to assess incontinence)'; changed the 'Adverse events' outcome heading to 'Other adverse events'; removed the adverse events outcomes 'Major vascular or visceral injury', 'Bladder or urethral perforation', 'Nerve damage', 'Other perioperative surgical complications', 'De novo urge symptoms or urge incontinence' and 'Erosion or fistula to vagina'; changed the adverse events outcome 'Other serious adverse events reported by individual trials' to 'Other adverse events reported by individual trials'. We also removed the quantification of symptoms secondary outcome 'Incontinence episodes' due to overlap with other outcomes. In response to editorial and peer referee feedback, we changed the classification of the 'Repeat continence surgery' outcome from the 'Other adverse events' outcome heading to instead represent a separate outcome heading and outcome, 'Repeat continence surgery: number of women undergoing repeat continence surgery'. Additionally, we added the subheading 'Main outcomes for 'Summary of findings table" and listed there the outcomes included in the 'Summary of findings' table, as the main outcomes were not specified in the protocol.
In the Methods section 'Data extraction and management', we clarified that data abstraction was performed independently by two review authors. We also added the following statement to clarify the specific data extracted: "Extracted data included study design; dates when the study was conducted; setting; participant inclusion and exclusion criteria; participant age; sample size of the study and of each intervention group; details of interventions; details of outcomes relevant to the review including how measured, time points at which they were measured and outcomes data; details of funding sources; declarations of interest among primary study authors; and study details relevant to risk of bias assessment."
In the Methods section 'Assessment of risk of bias in included studies', we updated the risk of bias judgements to 'low', 'unclear' or 'high' risk of bias and updated the risk of bias domain names for consistency with the current version of tool for assessing risk of bias of The Cochrane Collaboration (Higgins 2011a). We also clarified that each risk of bias for blinding of participants and personnel, blinding of outcome assessment and incomplete outcome data was assessed on an outcome-specific basis.
We expanded the Methods section 'Measures of treatment effect' to clarify the data that we sought and used to calculate the stated measures of treatment effect.
In the Methods section 'Unit of analysis issues', we clarified that no studies with multiple intervention groups were identified although they were eligible for inclusion.
In the protocol we had planned to analyse all data by intention-to-treat analysis, imputing missing data with replacement values. However, in the review we based analyses on available data only and addressed missing data in the risk of bias assessment in accordance with guidance provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011c). We revised the Methods section 'Dealing with missing data' to reflect this change.
As only one study was included in the review, it was neither necessary to assess heterogeneity nor to test for funnel plot asymmetry to assess potential publication bias, as we had planned in the protocol.
We attempted to obtain study protocols to assess for reporting bias in accordance with Cochrane standards, and we added a statement to the Methods section 'Assessment of reporting biases' to reflect this.
In the protocol, we planned to pool data from eligible studies in a meta-analysis, but this was not possible as only one study was included in the review. We also clarified the meta-analysis methods that we planned to use in the review as the Mantel-Haenszel method for dichotomous data and the inverse variance method for continuous data, as these methods were not specified in the protocol. We revised the Methods section 'Data synthesis' to reflect these changes.
We were unable to perform the predefined subgroup analyses because identified data were limited, and we reported a post hoc subgroup analysis by degree of baseline UI as performed in the included trial. We updated the Methods section 'Subgroup analysis and investigation of heterogeneity' accordingly.
We were unable to perform a predefined sensitivity analysis according to methodological quality, given the paucity of data. We indicated this in the Methods section 'Sensitivity analysis'.
We moved the description of methods used to rate the quality of evidence and to prepare a 'Summary of findings' table from the Methods section 'Assessment of risk of bias in included studies' to the Methods section "Summary of findings' table'.
